{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:45:15Z","timestamp":1764510315112},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":4583,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seventy patients with previously untreated advanced Hodgkin's disease and without bulky disease were entered in a prospective randomized clinical trial comparing epirubicin in combination with vinblastine, bleomycin, and dacarbazine (EVBD) with a regimen containing mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD). Both groups were comparable for the variables of age, sex, stage, and presence of B symptoms and histology. Thirty\u2010one (88%) of EVBD\u2010treated patients achieved a pathologically documented complete remission (CR) compared to the 24 cases (68%) of the MVBD\u2010treated group. After a median follow\u2010up of 36 months, duration of CR is better in the EVBD\u2010treated patients with an actuarial 5\u2010year duration of CR of 80%, statistically different to the MVBD group: 53% (P &lt; 0.01). Both regimens ahowed the same gastrointestinal toxicity, but the patients treated with the MVBD regimen shown most and severe hematological and cardiac toxicities. Also, biochemical alterations in hepatic test were observed in these patients. The alternative use of epirubicin in combination chemotherapy appears to be as effective in advanced Hodgkin's disease without bulky disease, with reduced clinical toxicity. Mitoxantrone containing regimen was not found to have an equivalent efficacy and clinical toxicity was most frequent and severe. We feld that mitoxantrone could be consider a second\u2010line drug in the treatment of advanced Hodgkin's disease. \u00a9 1994 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/mpo.2950220304","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T19:14:08Z","timestamp":1171998848000},"page":"168-172","source":"Crossref","is-referenced-by-count":8,"title":["Randomized study for the treatment of adult advanced Hodgkin's disease: Epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD)"],"prefix":"10.1002","volume":"22","author":[{"given":"Agust\u00edn","family":"Avil\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaldo","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Talavera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edna L.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 C.","family":"D\u00edaz\u2010Maqueo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1","article-title":"Chemotherapy in the treatment of Hodgkin's disease","volume":"20","author":"Canellos GB","year":"1983","journal-title":"Semin Hematol"},{"key":"e_1_2_1_3_2","first-page":"716","article-title":"The use of chemotherapy in the treatment of Hodgkin's disease","volume":"17","author":"Longo DL","year":"1990","journal-title":"Semin Oncol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(90)90017-M"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950140207"},{"key":"e_1_2_1_6_2","first-page":"758","article-title":"Survival outcome after Hodgkin's disease. A report from the International Data Base on Hodgkin's disease","volume":"17","author":"Henr\u2010Amar M","year":"1990","journal-title":"Semin Oncol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.9.1295"},{"key":"e_1_2_1_8_2","first-page":"34","article-title":"NOVP: A novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease","volume":"17","author":"Hagemeister FB","year":"1990","journal-title":"Semin Oncol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.5.754"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.3.425"},{"key":"e_1_2_1_11_2","first-page":"1063","article-title":"The pathology and nomenclature of Hodgkin's disease","volume":"26","author":"Lukes RJ","year":"1966","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","first-page":"288","article-title":"Report of the Committee on Hodgkin's disease: Staging classification","volume":"38","author":"Carbone P","year":"1976","journal-title":"Cancer Res"},{"key":"e_1_2_1_13_2","first-page":"615","article-title":"Valoraci\u00f3n de la funci\u00f3n ventricular en pacientes tratados con mitoxantrone y epirubicina","volume":"59","author":"Avil\u00e9s A","year":"1989","journal-title":"Arch Inst Cardiol Mex"},{"key":"e_1_2_1_14_2","first-page":"211","article-title":"La fosfatasa alcalina como factor pron\u00f3stico en enfermedad de Hodgkin","volume":"55","author":"Avit\u00e9s A","year":"1990","journal-title":"Rev Gastroenterol Mex"},{"key":"e_1_2_1_15_2","first-page":"341","article-title":"Enfermedad de Hodgkin tratada con quimioterapia a dosis reducidas","volume":"35","author":"Avil\u00e9s A","year":"1990","journal-title":"Sangre (Bare)"},{"key":"e_1_2_1_16_2","first-page":"45","article-title":"Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs LOPP","volume":"25","author":"Aviles A","year":"1991","journal-title":"Arch Invest Med"},{"key":"e_1_2_1_17_2","first-page":"121","volume-title":"Important Advances in Oncology","author":"Hryniuk WM","year":"1988"},{"key":"e_1_2_1_18_2","first-page":"5810","article-title":"The chemotherapy of lymphomas. Looking back moving forward","volume":"47","author":"De Vita VT","year":"1987","journal-title":"Cancer Res"},{"key":"e_1_2_1_19_2","unstructured":"World Health Organization: \u201cWHO Handbook for Reporting Results of Cancer Treatment.\u201d WHO Offset Publication No. 48. Geneva Switzerland: WHO 1979."},{"key":"e_1_2_1_20_2","volume-title":"Practical Nonparametric Statistics","author":"Conover WJ","year":"1980"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_22_2","volume-title":"Analysis of Survival Data","author":"Cox DR","year":"1984"},{"key":"e_1_2_1_23_2","first-page":"912","article-title":"Hepatotoxicity during administration of doxorubicin therapy","volume":"108","author":"Avil\u00e9s A","year":"1984","journal-title":"Arch Pathol Lab Med"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950220304","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950220304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:29:22Z","timestamp":1698150562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950220304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1002\/mpo.2950220304"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950220304","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}